CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for up to $2,171 per eligible Medicare patient case utilizing the Ceribell Delirium Monitor System.1

This follows the December 2025 U.S. Food and Drug Administration (FDA) 510(k) clearance of Ceribell’s proprietary Delirium Monitor System,2 establishing it as the first and only FDA-cleared device used to aid in delirium screening and monitoring.

The system continuously analyzes automated electroencephalogram (EEG) segments, notifying clinicians upon detecting patterns associated with delirium, to support rapid and objective treatment decision-making.

With the addition of the NTAP for delirium monitoring, the Ceribell Point-of-Care EEG platform now offers expanded coverage for critically ill patients. Built on Ceribell’s existing FDA-cleared technology for detecting nonconvulsive seizures and electrographic status epilepticus (ESE), this unified platform seamlessly integrates both seizure and delirium monitoring into a single system. By tracking multiple neurological vital signs simultaneously at the bedside, Ceribell equips providers with comprehensive diagnostic insights to manage co-occurring brain risks without requiring separate devices.

CMS established the NTAP process to identify and ensure adequate payment for certain new medical services and technologies under the Medicare Hospital Inpatient Prospective Payment System (IPPS). The add-on payment will take effect on Oct. 1, 2026.